Abbott Investors Ink $40M Deal Over Infant Formula Crisis
Shareholders who brought a derivative suit over Abbott Laboratories' management of the 2022 infant formula crisis asked an Illinois judge on Tuesday to approve a settlement that includes $40 million in...To view the full article, register now.
Already a subscriber? Click here to view full article